Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

8:30 AM ET 8-K
Contract Win Talen Energy Corp TLN

Talen Energy Wins $700M Contract from investment grade counterparty in PJM

Talen Energy's subsidiaries Guernsey Power Station and Waterford Power entered into capacity sale transactions with an investment grade counterparty in the PJM market. The primary Guernsey 7-Year Capacity Sale covers 750 MW of capacity from 2029 through 2036 and is expected to generate approximately $100 million in annual revenue.

Value
$700M
Counterparty
investment grade counterparty in PJM
Term
7 years
8:30 AM ET 10-Q
Financial Results Incannex Healthcare Inc. IXHL

Incannex Healthcare Q1 2026 Results: Net Loss of $1.94M, Loss Narrows

Incannex Healthcare Inc. reported a net loss from operations of $3.44 million for the quarter ended September 30, 2026, an improvement from a $6.79 million loss in the prior year period, primarily due to reduced general and administrative expenses. The company maintained a strong cash position of $68.27 million and continues to focus on its clinical development pipeline, including drug candidates IHL-42X and IHL-675A.

Key figure
Net loss $1.94M
8:30 AM ET 8-K
Clinical Trial Data Vivani Medical, Inc. VANI

Vivani Medical Clinical Trial Data

Vivani Medical announced positive top-line results from its SLIM-1 Phase 1 trial evaluating NPM-139, a miniature semaglutide implant for chronic weight management. The trial demonstrated that NPM-139 was well-tolerated with no treatment-related adverse events and achieved weight loss of 0.79% over four weeks, comparable to the 0.82% observed in the Wegovy control group.

Term
4 weeks

“The third quarter and recent weeks mark a period of strong progress and forward momentum for Vivani. The top-line SLIM-1 results will be announced this week. We look forward to sharing those results with shareholders, industry peers, and the broader community of physicians and patients seeking less frequent dosing and the promise of potential improvements in convenience, medication adherence, and tolerability associated with GLP-1 therapies on the market and in clinical-stage development.”

Adam Mendelsohn, PhD, CEO

“Roughly half of patients don’t take their medications for chronic diseases as prescribed, and GLP-1 therapies are no exception. With NPM-139, we are designing a novel GLP-1 therapy that a patient could receive once or twice a year during a routine primary care visit.”

Adam Mendelsohn, PhD, CEO
8:30 AM ET Form 4
Insider Buying Perspective Therapeutics, Inc. CATX

Perspective Therapeutics CEO Johan M. Spoor Buys $37.9K of Stock

Johan M. Spoor, CEO, bought 47,000 shares of Perspective Therapeutics, Inc. at $0.8073 a share, worth $37.9K in total on Nov 11, 2026. Shares held after the trade: 106,383 (+79.1%).

Value
$37.9K
Shares
47,000
Price
$0.8073
Role
CEO
Holding change
+79.1%
Trade date
Nov 11, 2026
8:26 AM ET 8-K
Financial Results SpyGlass Pharma, Inc. SGP

SpyGlass Pharma Financial Results

SpyGlass Pharma reported Q3 2026 financial results, highlighting a cash position of $215.8 million which is expected to fund operations through 2028. The company also announced the $13 million acquisition of Advanced Vision Science to secure IOL manufacturing capacity and reported positive four-year follow-up data from its first-in-human study of the BIM-IOL System.

Term
Q3 2026

“SpyGlass Pharma continued to execute our objectives over the course of the quarter as we aim to alter the treatment paradigm for glaucoma patients. Our underlying sustained drug delivery platform delivered four years of safety and efficacy results in the FIH trial of the BIM-IOL System, demonstrating that it can control IOP with unprecedented durability.”

Patrick Mooney, chief executive officer of SpyGlass Pharma
8:25 AM ET 8-K
Financial Results Ondas Inc. ONDS

Ondas Financial Results

Ondas reported record Q3 2026 revenue of $167.5 million, representing a 100% sequential increase and a 16-fold increase year-over-year. The company raised its full-year 2026 revenue target to at least $550 million and initiated a 2027 revenue target of at least $1.1 billion, driven by strong bookings and backlog growth.

“This quarter demonstrates the growing benefits of Ondas’ integrated operating platform. Our businesses are gaining access to larger customers, broader channels, and stronger production and field-support capabilities, allowing mission-ready technologies to move more quickly from evaluation into deployment.”

Eric Brock, Chairman and CEO of Ondas

“We expect a strong finish to 2026, with momentum accelerating in the fourth quarter as volume deliveries ramp across existing programs and we convert pipeline opportunities into customer programs.”

Eric Brock, Chairman and CEO of Ondas
8:25 AM ET 8-K
Loan & Debt Clarivate PLC CLVT

Clarivate $533M Debt Financing with Clarivate Science Holdings Corporation

Clarivate Plc announced the final results of cash tender offers to purchase its 3.875% Senior Secured Notes due 2028 and 4.875% Senior Notes due 2029. The company increased the acceptance amount and will purchase a total aggregate principal amount of $533 million of the notes. The 2028 and 2029 notes were accepted at proration factors of approximately 67.9% and 45.5%, respectively.

Value
$533M
Counterparty
Clarivate Science Holdings Corporation
8:22 AM ET 8-K
Loan & Debt Cornerstone Building Brands, Inc. CNR

Cornerstone Building Brands $500M Debt Financing with Monarch Alternative Capital LP

Cornerstone Building Brands entered into a $500 million term loan facility led by Monarch Alternative Capital LP to support operations and enhance liquidity. Separately, the company reached a non-binding agreement in principle with an ad hoc group of creditors holding 54% of its debt for a comprehensive recapitalization transaction supported by its equity sponsor, CD&R.

Value
$500M
Counterparty
Monarch Alternative Capital LP
Term
through Nov 2030
8:22 AM ET 10-Q
Financial Results CorMedix Inc. CRMD

CorMedix Q3 2026 Results: Net Loss of $14.7M

CorMedix Inc. reported net income of $49.9 million for the nine months ended September 30, 2026, a decrease from $149.0 million in the prior year period, primarily due to higher operating expenses and a significant tax benefit recorded in 2025. Total revenue and grant income grew to $283.9 million for the nine-month period, driven by product sales and new grant income.

Key figure
Net loss $14.7M
8:22 AM ET Form 4
Insider Selling Intuitive Surgical Inc ISRG

Intuitive Surgical EVP & Chief Legal and Complian Gary Loeb Sells $183K of Stock

Gary Loeb, EVP & Chief Legal and Complian, sold 400 shares of Intuitive Surgical Inc at $458.15 a share, worth $183K in total on Nov 10, 2026. Shares held after the trade: 6,236 (-6.0%).

Value
$183K
Shares
400
Price
$458.15
Role
EVP & Chief Legal and Complian
Holding change
-6.0%
Trade date
Nov 10, 2026
8:21 AM ET 8-K
Financial Results Corvex, Inc. MOVE

Corvex Financial Results

Corvex, Inc. reported third quarter 2026 financial results, its first full period following the divestiture of legacy healthcare assets. The company reported revenue of $5.0 million and a net loss of $17.5 million as it transitions to an AI computing platform model.

Term
Q3 2026

“We are building the Corvex AI Factory business one underwritten project at a time, and the third quarter moved that business forward. We have now secured all of the approximately 8 MW of critical IT capacity in the plan we set out in August.”

Jay Crystal, Co-Founder and Co-Chief Executive Officer

“Corvex is an engineering company first. In the third quarter we launched Corvex Token Factory on schedule and received notices of allowance for two patents covering Corvex’s technology, bringing our portfolio to two allowed patents and 10 pending patent applications.”

Seth Demsey, Co-Founder and Co-Chief Executive Officer
8:20 AM ET 8-K
Financial Results Leatt Corp LEAT

Leatt Financial Results

Leatt Corporation reported its highest quarterly revenues in four years, with Q3 2026 revenue increasing 43% to $20.46 million. Net income surged 309% to $2.20 million, driven by broad-based growth across body armor and helmet categories and the recoupment of global trade tariffs.

Term
Q3 2026

“The third quarter of 2026 was a strong quarter by nearly every measure. Total global revenues of $20.46 million were our highest in four years, up 43% over the third quarter of 2025.”

Sean Macdonald, Chief Executive Officer

“Net income for the third quarter increased by 309% to $2.20 million as compared to the third quarter of 2025. Gross profit increased by 48% to $9.32 million, in part due to the recoupment of global trade tariffs levied on the importation of goods into the U.S.”

Sean Macdonald, Chief Executive Officer
8:19 AM ET 10-Q
Financial Results Leatt Corp LEAT ▶ Call

Leatt Q3 2026 Results: Net Income $2.2M, Up 308.7% YoY

Leatt Corp reported strong growth for the third quarter of 2026, with revenues increasing 43% to $20.46 million and net income rising to $2.20 million compared to $0.54 million in the prior year period. For the nine months ended September 30, 2026, the company generated $4.59 million in net cash from operating activities and maintained a solid balance sheet with $15.43 million in cash and cash equivalents.

Key figure
Net income $2.2M · +308.7% YoY
8:18 AM ET 8-K
Leadership Change Filana Therapeutics, Inc. FLNA

Filana Therapeutics Leadership Change

Filana Therapeutics appointed Jill M. Quigley to its Board of Directors as a Class I director, effective November 8, 2026. Ms. Quigley brings over 20 years of biopharma leadership experience, including previous CEO and COO roles at Genuiti Therapeutics and Passage Bio. Her appointment is intended to support the company as it prepares for a Phase 2a clinical study of simufilam in TSC-related epilepsy.

8:18 AM ET 8-K
Financial Results RUM Group Inc. RUM

RUM Group Financial Results

RUM Group reported record Q3 2026 revenue of $96.6 million, a 290% year-over-year increase driven by the first full quarter of Quake AI contributions. The company achieved its first-ever profitable quarter on an Adjusted EBITDA basis, supported by high utilization of its 22,000 NVIDIA GPU fleet.

Term
Q3 2026

“Q3 was a defining quarter for RUM Group. We delivered record revenue, nearly four times last year’s, and achieved positive Adjusted EBITDA for the first time in our history. Quake AI is now the engine of our business. We have real assets running real AI workloads for real customers and generating real cash. Our 22,000-GPU estate is nearly sold out at 85% utilization. As capital becomes more selective, we believe it will flow to experienced operators with disciplined balance sheets. That is exactly where RUM Group stands, and we intend to use that position to build lasting value for our shareholders.”

Chris Pavlovski, CEO of RUM Group
8:17 AM ET Form 4
Insider Selling Sei Investments Co SEIC

Sei Investments Insider William Doran Sells $882K of Stock

William Doran sold 8,000 shares of Sei Investments Co at $110.30 a share, worth $882K in total on Nov 10, 2026. Shares held after the trade: 630,802 (-1.3%).

Value
$882K
Shares
8,000
Price
$110.30
Holding change
-1.3%
Trade date
Nov 10, 2026
8:16 AM ET 10-Q
Financial Results Theriva Biologics, Inc. TOVX

Theriva Biologics Q3 2026 Results: Net Loss of $1.47M, Loss Narrows

Theriva Biologics reported a net loss of $6.7 million for the nine months ended September 30, 2026, a significant improvement from the $21.7 million loss in the prior year period. The company generated $0.3 million in license revenue and substantially reduced operating expenses, while maintaining a cash balance of $8.5 million as of the end of the quarter.

Key figure
Net loss $1.47M
8:16 AM ET 10-Q
Financial Results Avalyn Pharma Inc. AVLN

Avalyn Pharma Q3 2026 Results: Net Loss of $29.7M, Loss Widens

Avalyn Pharma Inc. is a clinical-stage biopharmaceutical company focused on developing inhaled antifibrotic therapies for pulmonary fibrosis, specifically lead candidates AP01 and AP02. As of November 10, 2026, the company reported 44,521,494 shares of voting common stock outstanding and continues to incur significant operating losses to fund its research and development programs.

Key figure
Net loss $29.7M
8:16 AM ET 10-Q
Financial Results SeaStar Medical Holding Corp ICU

SeaStar Medical Holding Q3 2026 Results: Net Loss of $4.53M, Loss Widens

SeaStar Medical reported a net loss of $11.8 million for the nine months ended September 30, 2026, compared to $9.2 million in the prior year period, driven by increased research and development expenses. Total revenue grew to $1.7 million from $0.8 million year-over-year, while cash reserves decreased significantly to $4.0 million from $12.0 million at the start of the year.

Key figure
Net loss $4.53M
8:16 AM ET Form 4
Insider Buying Exagen Inc. XGN

Exagen Insider Jorey Chernett Buys $373K of Stock

Jorey Chernett bought 71,315 shares of Exagen Inc. at $5.23 a share, worth $373K in total on Nov 11, 2026. Shares held after the trade: 2,696,940 (+2.7%).

Value
$373K
Shares
71,315
Price
$5.23
Holding change
+2.7%
Trade date
Nov 11, 2026
8:16 AM ET 8-K
M&A Deal Trustmark Corp TRMK

Trustmark Signs $3.2B M&A Deal with Hancock Whitney Corporation

Trustmark Corporation has entered into a definitive agreement to merge with and into Hancock Whitney Corporation in an all-stock transaction valued at approximately $3.2 billion. The merger will create a premier Gulf South regional bank with approximately $58 billion in assets and is expected to close in the first quarter of 2027.

Value
$3.2B
Counterparty
Hancock Whitney Corporation
8:15 AM ET 8-K
Financial Results SES AI Corp SES

SES AI Financial Results

SES AI Corp reported its Q3 2026 financial results, highlighting a 31% sequential revenue increase to $6.6 million and a narrowing GAAP net loss of $13.4 million. The company successfully ramped its Chungju production line to 1 million cells per year and introduced its 'Flywheel' strategy focusing on drones, energy storage, and material discovery.

Term
3 years
8:15 AM ET 8-K
Product Launch Data443 Risk Mitigation, Inc. ATDS

Data443 Risk Mitigation Product Launch

Data443 Risk Mitigation announced the commercial launch of its Convaa.ai™ enterprise AI collaboration platform on the Apple App Store. The application is specifically optimized for the iPhone Duo foldable smartphone, allowing multi-person live AI collaboration sessions on the device's 7.6-inch inner display.

8:14 AM ET 8-K
Financial Results Suburban Propane Partners LP SPH

Suburban Propane Partners Financial Results

Suburban Propane Partners reported fiscal year 2026 net income of $109.0 million and Adjusted EBITDA of $284.0 million, a 2.2% increase over the prior year. The company highlighted strong heat-related demand in its propane segment and a 13% increase in average daily renewable natural gas (RNG) injections following facility upgrades and new capacity in New York.

Term
FY2026

“Fiscal 2026 was another strong year for Suburban Propane with solid results in our propane operations, the completion of capital projects to increase the scale of our renewable natural gas (“RNG”) business, and continued debt reduction to further strengthen our financial position.”

Michael A. Stivala, President and Chief Executive Officer

“With these investments in place, we enter fiscal 2027 with a larger, more reliable RNG platform, opportunities to increase production through capacity optimization and higher feedstock intake, and the ability to enhance our earnings profile from the recognition of additional PTCs.”

Michael A. Stivala, President and Chief Executive Officer
8:14 AM ET 8-K
Investor Presentation Dixie Group Inc DXYN

Dixie Group Investor Presentation

The Dixie Group, Inc. furnished an updated investor presentation for November 2026, superseding its previous presentation from August 2026. The materials provide a strategic overview of the company's history, its focus on the upper-end residential flooring market, and historical net sales data through 2025.

8:14 AM ET 10-Q
Financial Results MeiraGTx Holdings plc MGTX

MeiraGTx Holdings Q3 2026 Results: Net Loss of $51.2M, Loss Widens

MeiraGTx reported a significant increase in total revenue to $326.5 million for the nine months ended September 30, 2026, primarily driven by license and service revenue from related parties. This resulted in a net income of $63.1 million for the period, compared to a net loss of $129.3 million in the prior year, despite a net loss in the third quarter of 2026.

Key figure
Net loss $51.2M
8:13 AM ET 8-K
Financial Results Dixie Group Inc DXYN

Dixie Group Financial Results

The Dixie Group reported its third consecutive profitable quarter, with net sales increasing 4.6% to $65.2 million and net income of $577,000 compared to a significant loss in the prior year. The company attributed the improvement to cost reductions and operating efficiencies despite industry headwinds from high interest rates and inflation.

Term
Q3 2026

“We are pleased to report our third consecutive profitable quarter of 2026. Net sales increased 4.6% over the third quarter of last year, and we returned to operating income for the quarter compared to an operating loss in the prior year period. Gross profit margins improved to 26.6% from 24.8%, reflecting cost reductions and improved operating efficiencies in our operations.”

Daniel K. Frierson, Chairman and Chief Executive Officer
8:13 AM ET 8-K
Financial Results Forum Markets Inc FRMM

Forum Markets Financial Results

Forum Markets reported Q3 2026 revenue of $2.0 million and net income of $7.9 million, which included a $13.9 million non-cash gain from digital asset fair value changes. The company highlighted the formation of its Forum Edge AI joint venture and the acquisition of two additional commercial aircraft engines during the quarter.

Term
Q3 2026

“Over the past three months, we established our AI infrastructure platform through our Forum Edge AI joint venture and made it the primary focus of our capital and our growth. We have established the foundation for what we believe can become a substantial AI infrastructure business.”

McAndrew Rudisill, chairman and chief executive officer of Forum Markets

“The midterm elections significantly disrupted an already tightening AI compute market, accelerating rising costs for equipment, compute and financing. These conditions increase the value of data center capacity that is already permitted, powered and built, which is exactly what Forum has.”

McAndrew Rudisill, chairman and chief executive officer of Forum Markets

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.